Arain Its not unusual for Co's to go past the projected completion time listed on the clinical trials .gov site .
What is unusual for for Dr Javitt to state in an interview several weeks ago that they would see top line data in about 4 wks ( early Oct ) ...but the Co state today in a press release ...top line data expected before end of year .
I think the stock would have reacted a lot better if the Co had confirmed what Dr Javitt said ....or at least said they expect top line data before end of Oct.
Aug 12th Dr Javitts said there were 86 or 87 patients enrolled in the IV trial ......and my rough guess is that they had averaged at least 1 new patient enrolled per day since they had multiple sites up and running and based on past enrollment numbers .
So we need an update on the IV trial
Dr Javitt did announce there would be a partnership deal announced ......we didn't expect the one we got ...ie Neurorx would be our 50% partner for the US market .
Dr Javitts also stated Aug 12th ... " By October we should be able to manufacture enough drug for 100,00 people a month .
Today we learn from RLFTF ...thats 150,00 patients a month but by JAN 2021
So so far what Dr Javitts predicts will happen does ...just often a lot later than he originally states .
Kiwi
News 
Market Data 
Discover 
